Trial · NCT00514046
Adverse events2,295
Each adverse event the trial posted, group by group: the participants affected out of those at risk.
1 to 20 of 2,295
Download this page as JSON| Type | Event | Organ system | Group | Affected | At risk | Events |
|---|---|---|---|---|---|---|
| other | ALT, SGPT (serum glutamic pyruvic transaminase) | Metabolism and nutrition disorders | Vandetanib: First 100 mg/m^2, Then 150 mg/m^2 | 4 | 5 | 30 |
| other | ALT, SGPT (serum glutamic pyruvic transaminase) | Metabolism and nutrition disorders | Vandetanib: First 100mg/m^2, Then 150mg/m^2, Followed by 67mg | 0 | 1 | 0 |
| other | ALT, SGPT (serum glutamic pyruvic transaminase) | Metabolism and nutrition disorders | Vandetanib 100 mg/m^2 | 3 | 5 | 17 |
| other | ALT, SGPT (serum glutamic pyruvic transaminase) | Metabolism and nutrition disorders | Vandetanib: First 100mg/m^2, Then 150mg/m^2, Followed by 100mg | 1 | 1 | 2 |
| other | ALT, SGPT (serum glutamic pyruvic transaminase) | Metabolism and nutrition disorders | Vandetanib:First 100mg/m^2, Then 63mg, 42, 21, 42, & 21mg/m^2 | 1 | 1 | 2 |
| other | ALT, SGPT (serum glutamic pyruvic transaminase) | Metabolism and nutrition disorders | Vandetanib: First 100 mg/m^2, Then 70 mg/m^2 | 1 | 1 | 8 |
| other | ALT, SGPT (serum glutamic pyruvic transaminase) | Metabolism and nutrition disorders | Vandetanib: First 100mg/m^2, Then 150mg/m^2, Followed by 200mg | 1 | 1 | 3 |
| other | ALT, SGPT (serum glutamic pyruvic transaminase) | Metabolism and nutrition disorders | Vandetanib:First 100mg/m^2, Then 150mg, 100, 150, 100, 150mg | 1 | 1 | 5 |
| other | ALT, SGPT (serum glutamic pyruvic transaminase) | Metabolism and nutrition disorders | Vandetanib: First 150mg/m^2, Then 100mg/m^2, Followed by 150mg | 1 | 1 | 4 |
| other | AST, SGOT(serum glutamic oxaloacetic transaminase) | Metabolism and nutrition disorders | Vandetanib: First 100 mg/m^2, Then 150 mg/m^2 | 3 | 5 | 10 |
| other | AST, SGOT(serum glutamic oxaloacetic transaminase) | Metabolism and nutrition disorders | Vandetanib: First 100mg/m^2, Then 150mg/m^2, Followed by 67mg | 1 | 1 | 1 |
| other | AST, SGOT(serum glutamic oxaloacetic transaminase) | Metabolism and nutrition disorders | Vandetanib 100 mg/m^2 | 3 | 5 | 11 |
| other | AST, SGOT(serum glutamic oxaloacetic transaminase) | Metabolism and nutrition disorders | Vandetanib: First 100mg/m^2, Then 150mg/m^2, Followed by 100mg | 0 | 1 | 0 |
| other | AST, SGOT(serum glutamic oxaloacetic transaminase) | Metabolism and nutrition disorders | Vandetanib:First 100mg/m^2, Then 63mg, 42, 21, 42, & 21mg/m^2 | 0 | 1 | 0 |
| other | AST, SGOT(serum glutamic oxaloacetic transaminase) | Metabolism and nutrition disorders | Vandetanib: First 100 mg/m^2, Then 70 mg/m^2 | 1 | 1 | 7 |
| other | AST, SGOT(serum glutamic oxaloacetic transaminase) | Metabolism and nutrition disorders | Vandetanib: First 100mg/m^2, Then 150mg/m^2, Followed by 200mg | 0 | 1 | 0 |
| other | AST, SGOT(serum glutamic oxaloacetic transaminase) | Metabolism and nutrition disorders | Vandetanib:First 100mg/m^2, Then 150mg, 100, 150, 100, 150mg | 1 | 1 | 2 |
| other | AST, SGOT(serum glutamic oxaloacetic transaminase) | Metabolism and nutrition disorders | Vandetanib: First 150mg/m^2, Then 100mg/m^2, Followed by 150mg | 1 | 1 | 1 |
| other | Albumin, serum-low (hypoalbuminemia) | Metabolism and nutrition disorders | Vandetanib: First 100 mg/m^2, Then 150 mg/m^2 | 2 | 5 | 5 |
| other | Albumin, serum-low (hypoalbuminemia) | Metabolism and nutrition disorders | Vandetanib: First 100mg/m^2, Then 150mg/m^2, Followed by 67mg | 1 | 1 | 1 |
Source ClinicalTrials.govtrials-2026-11-12-0.5.0
Sources 3
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ClinicalTrials.govNo license stated
- NIH RePORTER's clinical studies and project filesPublic domain
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ClinicalTrials.govnone stated
- NIH RePORTER's clinical studies and project filesPublic domain (NIH RePORTER)
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this list from software.
Twenty rows a page, as JSON. No key.
GET https://conductscience.org/api/trials/v1/NCT00514046/events